(-0.16%) 5 205.25 points
(-0.05%) 39 009 points
(-0.19%) 18 165 points
(-0.94%) $77.64
(1.68%) $2.24
(-0.09%) $2 322.00
(-0.30%) $27.46
(-0.93%) $979.20
(0.10%) $0.930
(0.28%) $10.93
(0.13%) $0.800
(0.54%) $91.94
2 days till quarter result
(bmo 2024-05-10)
Expected move: +/- 10.58%
4.54% $ 9.67
@ $9.81
Wydano: 14 vas. 2024 @ 21:26
Zwrot: -1.38%
Poprzedni sygnał: vas. 14 - 16:30
Poprzedni sygnał:
Zwrot: 1.82 %
Live Chart Being Loaded With Signals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B...
Stats | |
---|---|
Dzisiejszy wolumen | 160 751 |
Średni wolumen | 344 945 |
Kapitalizacja rynkowa | 955.15M |
EPS | $-0.400 ( 2023-11-13 ) |
Następna data zysków | ( $-0.410 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.16 |
ATR14 | $0.0190 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Chao David M | Sell | 10 385 | Ordinary Shares |
2024-03-31 | Weinhoff Gregory M | Sell | 11 742 | Ordinary Shares |
2024-03-31 | Saha Saurabh | Sell | 36 263 | Ordinary Shares |
2024-03-31 | Hussain Iqbal J | Sell | 7 520 | Ordinary Shares |
2024-03-31 | Bush Tia L | Sell | 6 419 | Ordinary Shares |
INSIDER POWER |
---|
61.88 |
Last 100 transactions |
Buy: 3 998 584 | Sell: 832 725 |
Wolumen Korelacja
Centessa Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
SAIA | 0.939 |
LRGE | 0.938 |
VONG | 0.931 |
CYBR | 0.93 |
CACG | 0.93 |
FTC | 0.929 |
USMC | 0.929 |
COHR | 0.928 |
FTHI | 0.926 |
DEMZ | 0.925 |
10 Najbardziej negatywne korelacje | |
---|---|
BIOL | -0.909 |
HYRE | -0.907 |
DSWL | -0.899 |
WISA | -0.897 |
RTPY | -0.896 |
TLGT | -0.89 |
TCFC | -0.886 |
SGML | -0.886 |
SJ | -0.884 |
SQQQ | -0.884 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Centessa Pharmaceuticals Korelacja - Waluta/Towar
Centessa Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | $6.88M |
Zysk brutto: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2023 |
Przychody: | $6.88M |
Zysk brutto: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-130 919 (0.00 %) |
EPS: | $-2.31 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-4.05 |
Financial Reports:
No articles found.
Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej